DDInter1592 DDInter53
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alpelisib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Valproic acid
Valproic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may lead to a major life threatening interaction when taken with {v} Palbociclib
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Alpelisib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Valproic acid (Compound) and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rifapentine (Compound) resembles Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib